Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

CANF Stock Latest News

Company AnnouncementsCan-Fite Announces Eurasian Patent Allowance for Piclidenoson in Lowe Syndrome3d ago6K CANF

Company AnnouncementsCan-Fite Unveils Positive Final Phase IIa Pancreatic Cancer Data for Namodenoson at ESMO 20261w ago6K CANF
RatingsCan-Fite Buy Rating Reaffirmed as Clinical Momentum Builds and $8 Price Target Remains Unchanged1M agoCANF
Company AnnouncementsCan-Fite Case Report Shows Namodenoson Bridged Decompensated Cirrhosis Patient to Liver Transplant1M ago6K CANF
Company AnnouncementsCan-Fite BioPharma Reports Mid-2026 Results and Updates Drug Development Programs1M ago6K CANF

Can-Fite BioPharma Cuts Warrant Exercise Price to Secure $4 Million Inducement Financing

Company AnnouncementsCan-Fite BioPharma Cuts Warrant Exercise Price to Secure $4 Million Inducement Financing2M ago6K CANF

Company AnnouncementsCan-Fite BioPharma Raises $4 Million Through Warrant Exercise to Fund Late-Stage Drug Pipeline2M ago6K CANF

The FlyCan-Fite reports longer-than-anticipated survival observed in Namodenoson study2M agoCANF

Company AnnouncementsCan-Fite Flags Longer Survival in Phase III Liver Cancer Trial, Eyes Earlier Interim Analysis2M ago6K CANF
The FlyCan-Fite BioPharma files $100M mixed securities shelf2M agoCANF
Company AnnouncementsCan-Fite Reports New Data Supporting Namodenoson Combo Strategy in Pancreatic Cancer2M ago6K CANF
Company AnnouncementsCan-Fite BioPharma Advances Phase III Drug Candidates With Strengthened FDA and EMA Pathways2M ago6K CANF

Can-Fite submits Piclidenoson clinical study protocol to Bambino Gesu

The FlyCan-Fite submits Piclidenoson clinical study protocol to Bambino Gesu3M agoCANF

Company AnnouncementsCan-Fite BioPharma Starts First Piclidenoson Trial in Rare Lowe Syndrome3M ago6K CANF

Company AnnouncementsCan-Fite’s Namodenoson Pancreatic Cancer Data Accepted for ESMO 2026 Presentation3M ago6K CANF

Company AnnouncementsCan-Fite BioPharma Wins Australian Patent Backing Namodenoson in Liver and Pancreatic Cancer3M ago6K CANF
The FlyCan-Fite BioPharma secures Australian Patent Office allowance for namodenoson3M agoCANF
Company AnnouncementsCan-Fite Completes Key Phase 3 Psoriasis Enrolment Milestone for Piclidenoson4M ago6K CANF
The FlyCan-Fite BioPharma enrolls 247 patients in Piclidenoson trial4M agoCANF

Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright

The FlyCan-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright4M agoCANF

Company AnnouncementsCan-Fite’s Namodenoson Hits Safety Goal and Shows Durable Survival in Phase 2a Pancreatic Cancer Trial4M ago6K CANF

The FlyCan-Fite BioPharma announces Namodenoson study meets primary safety endpoint4M agoCANF